The Cancer Letter

Inside information on cancer research and drug development

Clinical

First-line immunotherapy treatment can improve survival for subset of lung cancer patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique molecular characteristics of their tumor, according to a new study reported by a global team led by David Carbone of Ohio State University Comprehensive Cancer–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

MD Anderson’s Lauren Averett Byers receives TAMEST O’Donnell Award

Lauren Averett Byers, professor of thoracic/head & neck medical oncology at the University of Texas MD Anderson Cancer Center, received the 2025 Edith and Peter O’Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology. The award recognizes her fundamental discoveries and contributions to identifying novel therapeutic strategies for small cell lung cancer, which have paved the way for personalized treatments, even in the most highly recalcitrant cancers.
In Brief

Break Through Cancer launches the PoweRD 2 Cure ALK+ Lung Cancer TeamLab

Break Through Cancer has launched the PoweRD 2 Cure ALK+ Lung Cancer TeamLab, a collaboration among nine leading cancer research institutions, including Break Through Cancer’s five partner institutions: Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, MIT’s Koch Institute for Integrative Cancer Research, and the University of Texas MD Anderson Cancer Center, as well as newly engaged collaborators from Mass General Brigham, Boston Children’s Hospital, the University of Colorado Cancer Center and Vanderbilt University Medical Center.
Clinical Roundup

Tecentriq + tiragolumab does not improve OS, updated phase III data finds

Genentech’s phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq (atezolizumab) compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer, did not reach the primary endpoint of overall survival at the final analysis. The overall safety profile observed remained consistent with longer follow-up, and no new safety signals were identified. The detailed data will be presented at a medical meeting in 2025.
Drugs & Targets

Merus and Partner Therapeutics announce license agreement for the U.S. commercialization of zenocutuzumab in NRG1 fusion-positive cancer

Merus a clinical-stage oncology company developing innovative, full-length multispecific antibodies and Partner Therapeutics Inc., a private, fully-integrated biotechnology company with a focus in hematology and oncology, announced they have entered into an agreement in which Merus has exclusively licensed to PTx the right to commercialize zenocutuzumab (Zeno, also called Bizengri) for the treatment of NRG1 fusion-positive cancer in the U.S.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account